Impact of Access Challenges on Patient Outcomes in CLL and MCL Care

EP: 1.Emerging BTKi Combinations in CLL: A New Frontier of Treatment Options

EP: 2.Clinical Implications and Unmet Needs in CLL BTKi Therapies

EP: 3.Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma

EP: 4.Integrating Emerging BTKi Therapies Into Current Treatment Guidelines

EP: 5.Future Directions and Research Priorities in BTKi Treatment Approaches

EP: 6.Latest Trends and Innovations in CLL and MCL Treatment

EP: 7.CLL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

EP: 8.Navigating CLL Treatment Choices

EP: 9.Therapy Sequencing in CLL

EP: 10.MCL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

EP: 11.MCL Therapy Selection and Sequencing

EP: 12.Impact of Patient-Reported Outcomes and Real-World Evidence in CLL and MCL

EP: 13.Latest ASH Updates: Clinical Use of BTK Inhibitors in Management of CLL and MCL

EP: 14.Impact of BTK Inhibitors on Treatment Paradigm of CLL and MCL

EP: 15.Patient-Centered Selection of BTK Inhibitors: Balancing Clinical Factors and Patient Preferences

EP: 16.Implementation of Shared Decision-Making in BTK Inhibitor Treatment

EP: 17.Optimizing BTK Inhibitor Treatment: Managing Adverse Effects and Adherence

EP: 18.Future Directions and Overcoming Challenges in BTK Inhibitor Therapy

Now Viewing

EP: 19.Impact of Access Challenges on Patient Outcomes in CLL and MCL Care

EP: 20.Balancing Clinical Benefits and Costs of BTK Inhibitors

Video content above is prompted by the following:

The treatment landscape for chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) has significantly advanced with the development of Bruton tyrosine kinase (BTK) inhibitors, offering improved efficacy and safety over traditional chemotherapy. However, access to these novel agents remains a significant barrier. The high cost—averaging around $15,000 per month—and the need for indefinite treatment pose financial burdens for patients and healthcare systems alike. These economic challenges are compounded by disparities in access to diagnostic tools and specialized care, particularly in regions where these diseases are less frequently encountered.

Prognostic testing plays a critical role in guiding treatment decisions, especially since CLL and MCL can be driven by specific molecular markers that influence treatment response. Yet, studies have shown that many patients still do not receive appropriate biomarker testing, which can lead to the continued use of outdated, less effective chemotherapy regimens. This not only impacts clinical outcomes but can also increase the risk of toxicity and hospitalizations. The lack of physician familiarity with the latest therapies in non-specialist settings may also contribute to suboptimal prescribing practices, further widening the treatment gap.

Addressing these challenges requires a multifaceted approach, including increased provider education, greater patient awareness, and policy-level changes to improve affordability and access to targeted therapies. Expanding access to prognostic testing and ensuring insurance coverage for novel agents are essential to shifting the standard of care. As these innovative treatments become more central to managing CLL and MCL, improving access will be critical to realizing their full potential—enhancing survival, reducing toxicity, and ultimately delivering better outcomes for patients across all care settings.